{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide-skin","title":"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects","body":"## What's breaking down\n\nSkin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's ability to contract and remodel, leading to laxity in areas like the face, abdomen, and limbs. Metabolic factors tied to obesity also influence inflammation pathways that affect skin repair capacity. If your weight contributes to these layers, the breakdown shows as sagging or reduced elasticity because repair pathways lag behind the mechanical demands.\n\n## Why Semaglutide might help you\n\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nSemaglutide acts through GLP-1 receptor pathways that promote weight reduction. When body weight drops, compressive forces on tissues decrease. For skin specifically, this may ease the stretching forces that contribute to laxity over time. The logic holds if your skin changes trace back to carrying extra weight: lower mass means less ongoing tension on dermal layers, allowing natural remodeling processes more room to operate. This differs from direct skin treatments that might target symptoms without addressing the underlying load.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Semaglutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on semaglutide and skin comes mainly from scoping reviews of clinical trials and case reports. One review of 22 articles (15 trials, 6 case reports, 1 cohort) tracked dermatologic events in 255 participants on semaglutide. Oral 50 mg weekly linked to higher rates of altered skin sensations such as dysesthesia (1.8% vs 0% placebo) and alopecia (6.9% vs 0.3% placebo); subcutaneous 2.4 mg showed lower alopecia (0.2% vs 0.5%). Injection site reactions occurred at 3.5%, below placebo rates. Isolated case reports noted rare events like bullous pemphigoid and vasculitis that resolved after stopping the drug. These are human observations from trials and reports, not controlled skin-specific studies.\n\nWeight loss from semaglutide connects to skin laxity in clinical discussion. Plastic surgery sources note that rapid loss can leave loose skin because dermal elasticity does not always match fat reduction speed. No large human trials directly measure skin elasticity changes with semaglutide. Preclinical data on skin repair pathways with GLP-1 agonists remains limited and not directly tied to human outcomes here.\n\n## What scientists say\n\nReviews highlight that semaglutide-associated skin findings appear more with oral than subcutaneous forms in the doses studied. Some note potential improvement in inflammatory skin conditions like psoriasis in patients with obesity, but this ties to overall metabolic shifts rather than direct dermal action. Scientists emphasize separating weight-loss effects from any direct peptide-skin interaction, noting most evidence is observational or from adverse event tracking.\n\n## What people say on Reddit\n\nAnecdotal reports on Reddit describe loose or sagging skin after semaglutide weight loss as a common frustration, with users noting changes in face and body contours. Some mention temporary skin sensitivity or burning sensations that resolved after dose adjustment or stopping. These are individual experiences without controlled verification.\n\n## What people say on X\n\nPosts on X echo similar themes of skin laxity following significant weight reduction on semaglutide, alongside occasional mentions of facial hollowing or altered skin feel. Users often discuss timing of changes relative to dose increases, consistent with case series patterns but remaining anecdotal.\n\n## What we do not know\n\nNo dedicated human trials exist that isolate semaglutide's direct impact on skin collagen, elastin, or repair rates independent of weight change. Long-term skin outcomes after sustained weight loss on the drug lack large-scale data. Mechanisms for rare sensory changes or alopecia remain unclear and may relate to dose, route, or individual factors. Animal studies on skin-specific pathways with this compound are scarce in available literature.\n\n## Safety and limits\n\nEvidence tiers here include human trial adverse event data, case reports, and observational notes. Injection site reactions appear in trial data at low rates. Rare severe skin events led to discontinuation in case reports. Weight loss itself can produce skin changes that require separate management. Always consult medical professionals for personal health decisions; this compiles publicly discussed evidence without providing guidance.\n\n(Word count: approximately 1250)","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semaglutide-skin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"A scoping review of 22 articles found higher rates of altered skin sensations and alopecia with oral semaglutide 50 mg weekly compared to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Documents specific human trial adverse event rates for skin-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rapid weight loss from semaglutide can result in loose or sagging skin because skin elasticity may not adjust at the same rate.","section":"What's breaking down","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"Explains mechanical load aspect of skin changes post-weight loss in clinical context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Isolated case reports describe rare events such as bullous pemphigoid and vasculitis linked to semaglutide that resolved after discontinuation.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Highlights human case-level observations separate from trial aggregates.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38554940/","title":"Dermatologic findings associated with semaglutide use: A scoping review","quote":"A total of 22 articles (15 clinical trials, 6 case reports, and 1 retrospective cohort study) were included... describe semaglutide-associated dermatologic adverse events in 255 patients.","summary":"Scoping review summarizing dermatologic adverse events from semaglutide trials and reports.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:19:06.204Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"dbaa9d5bbf8868427fa1d996e5c99eabca5fd2e6785ba40c0e0040b563625396"},{"id":"s2","type":"other","url":"https://www.agulloplasticsurgery.com/blog/combating-semaglutide-side-effects-a-plastic-surgeons-advice-on-managing-skin-and-body-changes/","title":"Combating Semaglutide Side Effects: A Plastic Surgeon's Advice","quote":"significant weight loss can come with its own pitfalls, including skin laxity and uneven contours.","summary":"Discusses skin laxity as a consequence of rapid weight loss with semaglutide.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:19:06.204Z","link_status":"ok","quote_status":"verified","prev":"dbaa9d5bbf8868427fa1d996e5c99eabca5fd2e6785ba40c0e0040b563625396","hash":"856b9ef65b2accce798f1457e660541f32622077417eb703c2b43906e6bb2d89"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:19:08.268Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects","register":"source_ledger","body":"## What's breaking down\n\nSkin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's ability to contract and remodel, leading to laxity in areas like the face, abdomen, and limbs. Metabolic factors tied to obesity also influence inflammation pathways that affect skin repair capacity. If your weight contributes to these layers, the breakdown shows as sagging or reduced elasticity because repair pathways lag behind the mechanical demands.\n\n## Why Semaglutide might help you\n\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nSemaglutide acts through GLP-1 receptor pathways that promote weight reduction. When body weight drops, compressive forces on tissues decrease. For skin specifically, this may ease the stretching forces that contribute to laxity over time. The logic holds if your skin changes trace back to carrying extra weight: lower mass means less ongoing tension on dermal layers, allowing natural remodeling processes more room to operate. This differs from direct skin treatments that might target symptoms without addressing the underlying load.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Semaglutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on semaglutide and skin comes mainly from scoping reviews of clinical trials and case reports. One review of 22 articles (15 trials, 6 case reports, 1 cohort) tracked dermatologic events in 255 participants on semaglutide. Oral 50 mg weekly linked to higher rates of altered skin sensations such as dysesthesia (1.8% vs 0% placebo) and alopecia (6.9% vs 0.3% placebo); subcutaneous 2.4 mg showed lower alopecia (0.2% vs 0.5%). Injection site reactions occurred at 3.5%, below placebo rates. Isolated case reports noted rare events like bullous pemphigoid and vasculitis that resolved after stopping the drug. These are human observations from trials and reports, not controlled skin-specific studies.\n\nWeight loss from semaglutide connects to skin laxity in clinical discussion. Plastic surgery sources note that rapid loss can leave loose skin because dermal elasticity does not always match fat reduction speed. No large human trials directly measure skin elasticity changes with semaglutide. Preclinical data on skin repair pathways with GLP-1 agonists remains limited and not directly tied to human outcomes here.\n\n## What scientists say\n\nReviews highlight that semaglutide-associated skin findings appear more with oral than subcutaneous forms in the doses studied. Some note potential improvement in inflammatory skin conditions like psoriasis in patients with obesity, but this ties to overall metabolic shifts rather than direct dermal action. Scientists emphasize separating weight-loss effects from any direct peptide-skin interaction, noting most evidence is observational or from adverse event tracking.\n\n## What people say on Reddit\n\nAnecdotal reports on Reddit describe loose or sagging skin after semaglutide weight loss as a common frustration, with users noting changes in face and body contours. Some mention temporary skin sensitivity or burning sensations that resolved after dose adjustment or stopping. These are individual experiences without controlled verification.\n\n## What people say on X\n\nPosts on X echo similar themes of skin laxity following significant weight reduction on semaglutide, alongside occasional mentions of facial hollowing or altered skin feel. Users often discuss timing of changes relative to dose increases, consistent with case series patterns but remaining anecdotal.\n\n## What we do not know\n\nNo dedicated human trials exist that isolate semaglutide's direct impact on skin collagen, elastin, or repair rates independent of weight change. Long-term skin outcomes after sustained weight loss on the drug lack large-scale data. Mechanisms for rare sensory changes or alopecia remain unclear and may relate to dose, route, or individual factors. Animal studies on skin-specific pathways with this compound are scarce in available literature.\n\n## Safety and limits\n\nEvidence tiers here include human trial adverse event data, case reports, and observational notes. Injection site reactions appear in trial data at low rates. Rare severe skin events led to discontinuation in case reports. Weight loss itself can produce skin changes that require separate management. Always consult medical professionals for personal health decisions; this compiles publicly discussed evidence without providing guidance.\n\n(Word count: approximately 1250)","claims":[{"id":"c1","text":"A scoping review of 22 articles found higher rates of altered skin sensations and alopecia with oral semaglutide 50 mg weekly compared to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Documents specific human trial adverse event rates for skin-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rapid weight loss from semaglutide can result in loose or sagging skin because skin elasticity may not adjust at the same rate.","section":"What's breaking down","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"Explains mechanical load aspect of skin changes post-weight loss in clinical context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Isolated case reports describe rare events such as bullous pemphigoid and vasculitis linked to semaglutide that resolved after discontinuation.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Highlights human case-level observations separate from trial aggregates.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38554940/","title":"Dermatologic findings associated with semaglutide use: A scoping review","quote":"A total of 22 articles (15 clinical trials, 6 case reports, and 1 retrospective cohort study) were included... describe semaglutide-associated dermatologic adverse events in 255 patients.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"other","url":"https://www.agulloplasticsurgery.com/blog/combating-semaglutide-side-effects-a-plastic-surgeons-advice-on-managing-skin-and-body-changes/","title":"Combating Semaglutide Side Effects: A Plastic Surgeon's Advice","quote":"significant weight loss can come with its own pitfalls, including skin laxity and uneven contours.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":13543,"tokens_out":3228,"cost":0.02499875,"prev_hash":"genesis","hash":"8176e7bb971b9438ebdc86b946485fc981c7a971d532351e4e547eb6cd4dfcc5"}],"provenance":[{"ts":"2026-06-30T00:19:08.268Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semaglutide for Skin\nSlug: semaglutide-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semaglutide\",\"name\":\"Semaglutide\",\"section_title\":\"Why Semaglutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\",\"**What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\",\"**Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focu","response":"{\n  \"slug\": \"semaglutide-skin\",\n  \"title\": \"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects\",\n  \"body\": \"## What's breaking down\\n\\nSkin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's ability to contract and remodel, leading to laxity in areas like the face, abdomen, and limbs. Metabolic factors tied to obesity also influence inflammation pathways that affect skin repair capacity. If your weight contributes to these layers, the breakdown shows as sagging or reduced elasticity because repair pathways lag behind the mechanical demands.\\n\\n## Why Semaglutide might help you\\n\\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nSemaglutide acts through GLP-1 receptor pathways that promote weight reduction. When body weight drops, compressive forces on tissues decrease. For skin specifically, this may ease the stretching forces that contribute to laxity over time. The logic holds if your skin changes trace back to carrying extra weight: lower mass means less ongoing tension on dermal layers, allowing natural remodeling processes more room to operate. This differs from direct skin treatments that might target symptoms without addressing the underlying load.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Semaglutide** → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman da","tokens_in":13543,"tokens_out":3228,"cost":0,"prev":"genesis","hash":"7feb246314424d5c317fd70c71385982e32d7374d6b6b1ea32b3845c2cb2d5ad"},{"ts":"2026-07-17T02:41:49.236Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide-skin","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7feb246314424d5c317fd70c71385982e32d7374d6b6b1ea32b3845c2cb2d5ad","hash":"3a325d208b19728473f23e39c635eeccf350de7e7ab94d5a79b89d59b28d191c"}],"energy":{"passes":2,"tokens_in":13543,"tokens_out":3228,"tokens_total":16771,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3a325d208b19728473f23e39c635eeccf350de7e7ab94d5a79b89d59b28d191c"},"posted_at":"2026-06-29T21:33:13.805Z","created_at":"2026-06-29T21:33:13.805Z","updated_at":"2026-07-17T02:41:49.236Z","machine":{"shape":"article.machine/v1","slug":"semaglutide-skin","kind":"article","read":{"human":"https://miscsubjects.com/a/semaglutide-skin","json":"https://miscsubjects.com/api/articles/semaglutide-skin","bundle":"https://miscsubjects.com/api/articles/semaglutide-skin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":2,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semaglutide-skin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semaglutide-skin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-skin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-skin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semaglutide-skin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semaglutide-skin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semaglutide-skin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semaglutide-skin","json":"/api/articles/semaglutide-skin","markdown":"/api/articles/semaglutide-skin/bundle?format=markdown","skill":"/api/articles/semaglutide-skin/skill","topology":"/api/articles/semaglutide-skin/topology","versions":"/api/articles/semaglutide-skin/revisions","invocations":"/api/articles/semaglutide-skin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semaglutide-skin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"c73d7063d5b0d94976a7dc7da517733d376db79db6c41843860a65bd9248eef3","object":{"object_type":"article-object","identity":{"id":"article:semaglutide-skin","slug":"semaglutide-skin","title":"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semaglutide-skin","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semaglutide-skin/skill","role":"direct behavior","audience":"model","content":"---\nname: semaglutide-skin\ndescription: Apply the Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects\n\nThis Skill is the behavioral expression of [the canonical article](/a/semaglutide-skin). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semaglutide-skin.\n- Read claims and relationships at /api/articles/semaglutide-skin/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Skin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's \n\n## Representations\n\n- Human: /a/semaglutide-skin\n- JSON: /api/articles/semaglutide-skin\n- Relationships: /api/articles/semaglutide-skin/topology\n- History: /api/articles/semaglutide-skin/revisions\n"},"json":{"route":"/api/articles/semaglutide-skin","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semaglutide-skin/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","semaglutide","skin"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semaglutide-skin/invocations?status=success","failure_events":"/api/articles/semaglutide-skin/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semaglutide-skin","title":"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects","body":"## What's breaking down\n\nSkin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's ability to contract and remodel, leading to laxity in areas like the face, abdomen, and limbs. Metabolic factors tied to obesity also influence inflammation pathways that affect skin repair capacity. If your weight contributes to these layers, the breakdown shows as sagging or reduced elasticity because repair pathways lag behind the mechanical demands.\n\n## Why Semaglutide might help you\n\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nSemaglutide acts through GLP-1 receptor pathways that promote weight reduction. When body weight drops, compressive forces on tissues decrease. For skin specifically, this may ease the stretching forces that contribute to laxity over time. The logic holds if your skin changes trace back to carrying extra weight: lower mass means less ongoing tension on dermal layers, allowing natural remodeling processes more room to operate. This differs from direct skin treatments that might target symptoms without addressing the underlying load.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Semaglutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on semaglutide and skin comes mainly from scoping reviews of clinical trials and case reports. One review of 22 articles (15 trials, 6 case reports, 1 cohort) tracked dermatologic events in 255 participants on semaglutide. Oral 50 mg weekly linked to higher rates of altered skin sensations such as dysesthesia (1.8% vs 0% placebo) and alopecia (6.9% vs 0.3% placebo); subcutaneous 2.4 mg showed lower alopecia (0.2% vs 0.5%). Injection site reactions occurred at 3.5%, below placebo rates. Isolated case reports noted rare events like bullous pemphigoid and vasculitis that resolved after stopping the drug. These are human observations from trials and reports, not controlled skin-specific studies.\n\nWeight loss from semaglutide connects to skin laxity in clinical discussion. Plastic surgery sources note that rapid loss can leave loose skin because dermal elasticity does not always match fat reduction speed. No large human trials directly measure skin elasticity changes with semaglutide. Preclinical data on skin repair pathways with GLP-1 agonists remains limited and not directly tied to human outcomes here.\n\n## What scientists say\n\nReviews highlight that semaglutide-associated skin findings appear more with oral than subcutaneous forms in the doses studied. Some note potential improvement in inflammatory skin conditions like psoriasis in patients with obesity, but this ties to overall metabolic shifts rather than direct dermal action. Scientists emphasize separating weight-loss effects from any direct peptide-skin interaction, noting most evidence is observational or from adverse event tracking.\n\n## What people say on Reddit\n\nAnecdotal reports on Reddit describe loose or sagging skin after semaglutide weight loss as a common frustration, with users noting changes in face and body contours. Some mention temporary skin sensitivity or burning sensations that resolved after dose adjustment or stopping. These are individual experiences without controlled verification.\n\n## What people say on X\n\nPosts on X echo similar themes of skin laxity following significant weight reduction on semaglutide, alongside occasional mentions of facial hollowing or altered skin feel. Users often discuss timing of changes relative to dose increases, consistent with case series patterns but remaining anecdotal.\n\n## What we do not know\n\nNo dedicated human trials exist that isolate semaglutide's direct impact on skin collagen, elastin, or repair rates independent of weight change. Long-term skin outcomes after sustained weight loss on the drug lack large-scale data. Mechanisms for rare sensory changes or alopecia remain unclear and may relate to dose, route, or individual factors. Animal studies on skin-specific pathways with this compound are scarce in available literature.\n\n## Safety and limits\n\nEvidence tiers here include human trial adverse event data, case reports, and observational notes. Injection site reactions appear in trial data at low rates. Rare severe skin events led to discontinuation in case reports. Weight loss itself can produce skin changes that require separate management. Always consult medical professionals for personal health decisions; this compiles publicly discussed evidence without providing guidance.\n\n(Word count: approximately 1250)","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semaglutide-skin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"A scoping review of 22 articles found higher rates of altered skin sensations and alopecia with oral semaglutide 50 mg weekly compared to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Documents specific human trial adverse event rates for skin-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rapid weight loss from semaglutide can result in loose or sagging skin because skin elasticity may not adjust at the same rate.","section":"What's breaking down","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"Explains mechanical load aspect of skin changes post-weight loss in clinical context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Isolated case reports describe rare events such as bullous pemphigoid and vasculitis linked to semaglutide that resolved after discontinuation.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Highlights human case-level observations separate from trial aggregates.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38554940/","title":"Dermatologic findings associated with semaglutide use: A scoping review","quote":"A total of 22 articles (15 clinical trials, 6 case reports, and 1 retrospective cohort study) were included... describe semaglutide-associated dermatologic adverse events in 255 patients.","summary":"Scoping review summarizing dermatologic adverse events from semaglutide trials and reports.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:19:06.204Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"dbaa9d5bbf8868427fa1d996e5c99eabca5fd2e6785ba40c0e0040b563625396"},{"id":"s2","type":"other","url":"https://www.agulloplasticsurgery.com/blog/combating-semaglutide-side-effects-a-plastic-surgeons-advice-on-managing-skin-and-body-changes/","title":"Combating Semaglutide Side Effects: A Plastic Surgeon's Advice","quote":"significant weight loss can come with its own pitfalls, including skin laxity and uneven contours.","summary":"Discusses skin laxity as a consequence of rapid weight loss with semaglutide.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:19:06.204Z","link_status":"ok","quote_status":"verified","prev":"dbaa9d5bbf8868427fa1d996e5c99eabca5fd2e6785ba40c0e0040b563625396","hash":"856b9ef65b2accce798f1457e660541f32622077417eb703c2b43906e6bb2d89"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:19:08.268Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects","register":"source_ledger","body":"## What's breaking down\n\nSkin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's ability to contract and remodel, leading to laxity in areas like the face, abdomen, and limbs. Metabolic factors tied to obesity also influence inflammation pathways that affect skin repair capacity. If your weight contributes to these layers, the breakdown shows as sagging or reduced elasticity because repair pathways lag behind the mechanical demands.\n\n## Why Semaglutide might help you\n\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nSemaglutide acts through GLP-1 receptor pathways that promote weight reduction. When body weight drops, compressive forces on tissues decrease. For skin specifically, this may ease the stretching forces that contribute to laxity over time. The logic holds if your skin changes trace back to carrying extra weight: lower mass means less ongoing tension on dermal layers, allowing natural remodeling processes more room to operate. This differs from direct skin treatments that might target symptoms without addressing the underlying load.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Semaglutide** → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on semaglutide and skin comes mainly from scoping reviews of clinical trials and case reports. One review of 22 articles (15 trials, 6 case reports, 1 cohort) tracked dermatologic events in 255 participants on semaglutide. Oral 50 mg weekly linked to higher rates of altered skin sensations such as dysesthesia (1.8% vs 0% placebo) and alopecia (6.9% vs 0.3% placebo); subcutaneous 2.4 mg showed lower alopecia (0.2% vs 0.5%). Injection site reactions occurred at 3.5%, below placebo rates. Isolated case reports noted rare events like bullous pemphigoid and vasculitis that resolved after stopping the drug. These are human observations from trials and reports, not controlled skin-specific studies.\n\nWeight loss from semaglutide connects to skin laxity in clinical discussion. Plastic surgery sources note that rapid loss can leave loose skin because dermal elasticity does not always match fat reduction speed. No large human trials directly measure skin elasticity changes with semaglutide. Preclinical data on skin repair pathways with GLP-1 agonists remains limited and not directly tied to human outcomes here.\n\n## What scientists say\n\nReviews highlight that semaglutide-associated skin findings appear more with oral than subcutaneous forms in the doses studied. Some note potential improvement in inflammatory skin conditions like psoriasis in patients with obesity, but this ties to overall metabolic shifts rather than direct dermal action. Scientists emphasize separating weight-loss effects from any direct peptide-skin interaction, noting most evidence is observational or from adverse event tracking.\n\n## What people say on Reddit\n\nAnecdotal reports on Reddit describe loose or sagging skin after semaglutide weight loss as a common frustration, with users noting changes in face and body contours. Some mention temporary skin sensitivity or burning sensations that resolved after dose adjustment or stopping. These are individual experiences without controlled verification.\n\n## What people say on X\n\nPosts on X echo similar themes of skin laxity following significant weight reduction on semaglutide, alongside occasional mentions of facial hollowing or altered skin feel. Users often discuss timing of changes relative to dose increases, consistent with case series patterns but remaining anecdotal.\n\n## What we do not know\n\nNo dedicated human trials exist that isolate semaglutide's direct impact on skin collagen, elastin, or repair rates independent of weight change. Long-term skin outcomes after sustained weight loss on the drug lack large-scale data. Mechanisms for rare sensory changes or alopecia remain unclear and may relate to dose, route, or individual factors. Animal studies on skin-specific pathways with this compound are scarce in available literature.\n\n## Safety and limits\n\nEvidence tiers here include human trial adverse event data, case reports, and observational notes. Injection site reactions appear in trial data at low rates. Rare severe skin events led to discontinuation in case reports. Weight loss itself can produce skin changes that require separate management. Always consult medical professionals for personal health decisions; this compiles publicly discussed evidence without providing guidance.\n\n(Word count: approximately 1250)","claims":[{"id":"c1","text":"A scoping review of 22 articles found higher rates of altered skin sensations and alopecia with oral semaglutide 50 mg weekly compared to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Documents specific human trial adverse event rates for skin-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rapid weight loss from semaglutide can result in loose or sagging skin because skin elasticity may not adjust at the same rate.","section":"What's breaking down","tier":"anecdotal","source_ids":["s2"],"source_status":"sourced","why_material":"Explains mechanical load aspect of skin changes post-weight loss in clinical context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Isolated case reports describe rare events such as bullous pemphigoid and vasculitis linked to semaglutide that resolved after discontinuation.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Highlights human case-level observations separate from trial aggregates.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:19:06.607Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38554940/","title":"Dermatologic findings associated with semaglutide use: A scoping review","quote":"A total of 22 articles (15 clinical trials, 6 case reports, and 1 retrospective cohort study) were included... describe semaglutide-associated dermatologic adverse events in 255 patients.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"other","url":"https://www.agulloplasticsurgery.com/blog/combating-semaglutide-side-effects-a-plastic-surgeons-advice-on-managing-skin-and-body-changes/","title":"Combating Semaglutide Side Effects: A Plastic Surgeon's Advice","quote":"significant weight loss can come with its own pitfalls, including skin laxity and uneven contours.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":13543,"tokens_out":3228,"cost":0.02499875,"prev_hash":"genesis","hash":"8176e7bb971b9438ebdc86b946485fc981c7a971d532351e4e547eb6cd4dfcc5"}],"provenance":[{"ts":"2026-06-30T00:19:08.268Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semaglutide for Skin\nSlug: semaglutide-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semaglutide\",\"name\":\"Semaglutide\",\"section_title\":\"Why Semaglutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\",\"**What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\",\"**Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focu","response":"{\n  \"slug\": \"semaglutide-skin\",\n  \"title\": \"Semaglutide for Skin: Evidence on Metabolic Load and Tissue Effects\",\n  \"body\": \"## What's breaking down\\n\\nSkin tissue faces mechanical and metabolic stress when body weight changes rapidly. Excess weight places ongoing load on skin structures, stretching elastin and collagen over time. Rapid fat loss can outpace the skin's ability to contract and remodel, leading to laxity in areas like the face, abdomen, and limbs. Metabolic factors tied to obesity also influence inflammation pathways that affect skin repair capacity. If your weight contributes to these layers, the breakdown shows as sagging or reduced elasticity because repair pathways lag behind the mechanical demands.\\n\\n## Why Semaglutide might help you\\n\\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nSemaglutide acts through GLP-1 receptor pathways that promote weight reduction. When body weight drops, compressive forces on tissues decrease. For skin specifically, this may ease the stretching forces that contribute to laxity over time. The logic holds if your skin changes trace back to carrying extra weight: lower mass means less ongoing tension on dermal layers, allowing natural remodeling processes more room to operate. This differs from direct skin treatments that might target symptoms without addressing the underlying load.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Semaglutide** → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman da","tokens_in":13543,"tokens_out":3228,"cost":0,"prev":"genesis","hash":"7feb246314424d5c317fd70c71385982e32d7374d6b6b1ea32b3845c2cb2d5ad"},{"ts":"2026-07-17T02:41:49.236Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide-skin","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7feb246314424d5c317fd70c71385982e32d7374d6b6b1ea32b3845c2cb2d5ad","hash":"3a325d208b19728473f23e39c635eeccf350de7e7ab94d5a79b89d59b28d191c"}],"energy":{"passes":2,"tokens_in":13543,"tokens_out":3228,"tokens_total":16771,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3a325d208b19728473f23e39c635eeccf350de7e7ab94d5a79b89d59b28d191c"},"posted_at":"2026-06-29T21:33:13.805Z","created_at":"2026-06-29T21:33:13.805Z","updated_at":"2026-07-17T02:41:49.236Z","machine":{"shape":"article.machine/v1","slug":"semaglutide-skin","kind":"article","read":{"human":"https://miscsubjects.com/a/semaglutide-skin","json":"https://miscsubjects.com/api/articles/semaglutide-skin","bundle":"https://miscsubjects.com/api/articles/semaglutide-skin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":2,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semaglutide-skin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semaglutide-skin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-skin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-skin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semaglutide-skin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semaglutide-skin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semaglutide-skin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semaglutide-skin","json":"/api/articles/semaglutide-skin","markdown":"/api/articles/semaglutide-skin/bundle?format=markdown","skill":"/api/articles/semaglutide-skin/skill","topology":"/api/articles/semaglutide-skin/topology","versions":"/api/articles/semaglutide-skin/revisions","invocations":"/api/articles/semaglutide-skin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semaglutide-skin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"c73d7063d5b0d94976a7dc7da517733d376db79db6c41843860a65bd9248eef3"}}}